Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry
- G Horneff1,2,
- F De Bock1,
- I Foeldvari3,
- H J Girschick4,
- H Michels5,
- D Moebius6,
- H Schmeling2,7,
- and the German and Austrian Paediatric Rheumatology Collaborative Study Group
- 1Department of Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
- 2Department of Paediatrics, University Medical Centre, Martin Luther University, Halle-Wittenberg, Germany
- 3Paediatric Rheumatology Clinic, AK Eilbeck, Hamburg, Germany
- 4Department of Paediatrics, University Medical Centre, Wuerzburg, Germany
- 5Children’s Rheumatology Clinic, Garmisch-Partenkirchen, Germany
- 6Department of Paediatric Rheumatology, Carl-Thiem Hospital, Cottbus, Germany
- 7Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada
- Gerd Horneff, Asklepios Clinic Sankt Augustin, Department of Pediatrics, Arnold-Janssen Str. 29, 53757 Sankt Augustin;
- Accepted 9 April 2008
- Published Online First 15 April 2008
Objective: Etanercept monotherapy has been studied and approved for treatment of polyarticular juvenile idiopathic arthritis (JIA). The following study evaluates the safety and efficacy of combination therapy of etanercept and methotrexate compared to etanercept monotherapy in JIA.
Methods: We perfomed an open, non-randomised study on patients who had previously failed to respond to at least one disease-modifying antirheumatic drug (DMARD). A total of 722 patients with JIA in whom at least 1 item of follow-up data was recorded were identified; of these, 118 patients treated with further slow acting drugs were excluded. In all, 504 patients were treated with a combination of etanercept and methotrexate. A total of 100 patients treated with etanercept only were in the control group. Efficacy was calculated using the American College of Rheumatology paediatric scores for 30, 50 and 70% improvement (PedACR30/50/70). Adverse events (AEs) and serious adverse events (SAEs) were reported.
Results: After 12 months 55 patients in the monotherapy group and 376 patients in the etanercept and methotrexate group were available for comparison. For the intention to treat analysis, 65 patients discontinuing treatment prematurely were included. All activity parameters decreased significantly in both treatment groups. After 12 months 81%/74%/62% of patients of the etanercept and methotrexate group and 70%/63%/45% of patients of the etanercept monotherapy group achieved PedACR30/50/70 scores, respectively (p<0.05 for PedACR30, p<0.01 for PedACR70). The likelihood of achieving a PedACR70 increased with combination therapy with an odds ratio of 2.1 (95% CI 1.2 to 3.5). In total, 25 infectious and 23 non-infectious SAEs including 3 malignancies occurred in the etanercept and methotrexate group, and 1 infectious and 3 non-infectious SAEs occurred in the single etanercept group.
Conclusions: The patients’ disease activity improved during etanercept monotherapy and etanercept and methotrexate combination therapy. Tolerability in both treatment groups was comparable.
Competing interests: GH has been a member of the advisory boards for Wyeth Biopharma, Muenster, Germany, Abbott Pharma, Wiesbaden, Germany and Essex Pharma, Munich, Germany. GH is conducting clinical studies sponsored by Wyeth Biopharma, Muenster, Germany and Abbott Pharma, Wiesbaden, Germany.
Funding: The German Etanercept Registry is sponsored by Wyeth Biopharma, Muenster, Germany.
Ethics approval: Ethical approval was granted by the medical ethics committee at the site of the principal investigator (GH; Martin Luther University, Halle-Wittenberg, Germany); written consent was obtained and the data collected in pseudonymous form.